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Abstract: Alzheimer’s disease (AD) is the most common cause of dementia. Epidemiological studies
show the association between AD and type 2 diabetes (T2DM), although the mechanisms are not
fully understood. Dietary habits and lifestyle, that are risk factors in both diseases, strongly modulate
gut microbiota composition. Also, the brain-gut axis plays a relevant role in AD, diabetes and
inflammation, through products of bacterial metabolism, like short-chain fatty acids. We provide a
comprehensive review of current literature on the relation between dysbiosis, altered inflammatory
cytokines profile and microglia in preclinical models of AD, T2DM and models that reproduce both
diseases as commonly observed in the clinic. Increased proinflammatory cytokines, such as IL-1β and
TNF-α, are widely detected. Microbiome analysis shows alterations in Actinobacteria, Bacteroidetes
or Firmicutes phyla, among others. Altered α- and β-diversity is observed in mice depending on
genotype, gender and age; therefore, alterations in bacteria taxa highly depend on the models and
approaches. We also review the use of pre- and probiotic supplements, that by favoring a healthy
microbiome ameliorate AD and T2DM pathologies. Whereas extensive studies have been carried out,
further research would be necessary to fully understand the relation between diet, microbiome and
inflammation in AD and T2DM.
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1. Alzheimer’s Disease
Growing life expectancy is secondarily contributing to a significant rise of patholo-
gies associated with aging. Among them, dementias are specially relevant due to their
prevalence, economical costs and societal burden [1]. Alzheimer’s disease (AD) is the most
prevalent form of dementia, which may contribute to 60–70% of total cases [2], followed by
vascular dementia. AD neuropathological features include: amyloid pathology, neurofib-
rillary tangles and synaptic and neuronal loss [3]. Amyloid-β peptide (Aβ) can deposit
as extracellular senile plaques (SP) or cerebral amyloid angiopathy (CAA) surrounding
brain vessels. On the other hand, tau dysfunction includes hyper-phosphorylation and
aggregation of tau-protein in paired helical filaments, the major constituent of neurofib-
rillary tangles, which can cause neuron loss in AD [4,5]. Neuronal loss is a later step in
AD evolution and it is the pathological feature that best correlates with illness duration
and severity [6,7]. Whereas the vast majority of the AD cases are sporadic and the causes
unknown [8], neuropathological features and clinical phenotype are largely the same as in
familiar AD cases.
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Apart from classical neuropathological features of AD, other alterations have been
described, and the concept of neurodegeneration has expanded to accommodate early
alterations that include oxidative stress or inflammation [9]. Following this idea, neuroin-
flammation also plays a significant role in neurodegeneration [10]. In this sense, AD brains
suffer neuroinflammatory changes including alterations in morphology and distribution
of microglia and astrocytes, or increased expression of inflammatory mediators [11–13].
While microglia’s response to injury is typically beneficial, it can go awry in cases of chronic
injury and long-term inflammation, such as in AD. Thereby, microglia is chronically ac-
tivated in the proximity of amyloid plaques and limits amyloid plaque growth [14] but,
as the disease progresses, microglia fails to clear Aβ from brain parenchyma and ultimately
contributes to the neurodegenerative process [13,15,16].
On the other hand, growing evidence has shown that alterations in the gut microbiota
composition can alter normal brain function through the so-called gut–brain axis. Following
this idea, the bidirectional communication between the central nervous system (CNS) and
the gastrointestinal tract plays a key role in the pathogenesis of a variety of neuropsychiatric
disorders and AD [17]. Moreover, regulation of gut microbiota has been implicated in the
control of neuroinflammation and AD progression [18]. Additionally, in opposite direction,
AD pathology could affect gut microbiota composition [17,19].
2. Prediabetes and Type 2 Diabetes Mellitus
Metabolic disorders include several pathologies. Among these, diabetes mellitus (DM)
is one of the most prevalent diseases in the world. Moreover, type 2 diabetes (T2DM) is
one of the leading causes of premature morbidity and mortality and its incidence increases
with age [20,21]. The total number of people affected by DM is projected to rise up to
700 million in 2045 and about 90% of all the cases are of T2DM [22]. T2DM is characterized
by an initial stage of insulin resistance or prediabetes, caused by the inability of the cells
to fully respond to insulin, associated with blood glucose levels above the normal range
but below the diabetes diagnostic threshold [23]. Currently, the most accepted position
is that β-cell dysfunction, as impaired insulin secretion, is an independent abnormality
that precedes dysglycemia, on a background of insulin resistance [24]. Although the
development of this pathology shows high hereditability, T2DM seems to be caused by
a combination of lifestyle and genetic factors [25]. In this sense, T2DM prevalence is
increasing in children and younger adults, due to rising levels of obesity, sedentary lifestyle
and inappropriate diet [26,27].
Systemic inflammation also plays an important role in insulin resistance and the patho-
genesis of T2DM. The disease is associated to a pro-inflammatory state with a moderate
excess in the production of cytokines such as IL-6, IL-1 or tumor necrosis factor (TNF),
which hinder the interaction of insulin with its receptor and contribute to insulin resistance
and diabetes [28]. On the other hand, gut microbiota also seems to play a role in metabolic
disorders including obesity, prediabetes and T2DM by influencing glucose homeostasis
and insulin resistance, as well as by affecting digestion of sugars and production of gut
hormones that control this process [29–32]. Nevertheless, the strict control of glucose levels
in the gut is not only mediated by hormonal control but also by gut-brain axis control [33].
Moreover, gut dysbiosis may affect intestinal permeability, as well as the metabolism of
carbohydrates and their products [34,35]. Following this idea, T2DM patients show gut
microbial dysbiosis, including reduced abundance of some butyrate-producing bacteria
or increased opportunistic pathogens [36]. The decrease of short-chain fatty acids (SC-
FAs) may ultimately contribute to insulin resistance [37], that can be reverted by SCFAs
administration [38]. In this sense, the restoration of gut microbiota can improve metabolic
alterations, which position pre- and probiotics as an interesting option to prevent and/or
treat prediabetes and T2DM [31,39].
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3. AD-T2DM Relationship
Previous epidemiological studies have shown that T2DM is strongly associated
with cognitive impairment and late-onset AD [40–44]. Both pathologies, AD and T2DM,
share several pathophysiological features [45,46]. Whereas implicated mechanisms have
not been fully elucidated [47,48] inflammation, diet or gut microbiota have been analyzed
due to their possible role in the development of AD, as presented below.
3.1. Inflammation
Microglia responds to pathogens and modulates the immune response in the CNS [49].
Although brain neuroinflammation is considered a relevant player in neurodegenerative
diseases and AD [50,51] a cross-talk between peripheral and central inflammation has also
been described [52]. The dual role of microglia in AD has been largely addressed [53,54]
and whereas microglia may limit SP growth [14], uncontrolled chronic inflammation and re-
lease of neurotoxic factors, including inflammatory mediators and reactive oxygen species,
result in the exacerbation of AD pathology [55–57]. While brain inflammation is a hall-
mark associated with neurodegeneration in AD, peripheral blood inflammatory markers,
such as IL-6, TNF-α or TGF-β are detected in AD patients as well [58]. Additionally,
systemic inflammation plays an important role in the pathogenesis of prediabetes and
T2DM [59], given that the adipose tissue can overproduce pro-inflammatory cytokines
like TNF-α, which impairs insulin signalling, increasing the risk of insulin resistance [60].
Besides, TNF-α contributes to impair insulin signalling by increasing insulin receptor
substrate-1 phosphorylation [61]. Altogether, it seems that T2DM, or even prediabetes,
can cooperatively modulate the expression of brain pro-inflammatory cytokines in AD [12],
and both the prediabetic state and T2DM, promote microglia activation in AD mice [62–64],
supporting the role of the inflammatory process as a link between AD and T2DM.
3.2. Diet
Nutrition is considered a lifestyle factor that can modify the risk of dementia [65].
Nutrients reach the brain via the blood–brain barrier (BBB) by different mechanisms,
such as facilitated diffusion or active transport [66]. Several studies have shown the role
of specific nutrients, including folates and B12 vitamin, in brain volume loss in adult
patients [67,68]. One of the most important effects of the diet is the ability to promote
or control inflammation and therefore, neuroinflammation can be modified by a dietary
pattern [69]. In this sense, Mediterranean diet (MD), considered an anti-inflammatory
diet, is associated with preserved cognitive functions in elderly adults [70]. Ketogenic diet
may improve neuropathological and biochemical changes associated to AD [71] as well as
preserve cognition in patients with mild AD [72,73]. Likewise, studies in elderly patients
have shown the neuroprotective effects of caloric restriction on memory [74].
On the other hand, T2DM onset can be improved by modifying lifestyle, including
diet intervention [75]. Accordingly, healthy lifestyle with regular physical activity [76],
high dietary fiber intake [77] and anti-inflammatory diets, like the MD, have positive effects
on insulin secretion patterns [78]. Moreover, vegetarian diet also improves glycemic control
in patients [79,80]. Hence, given the close relation between AD and T2DM, diet may also
be an important link factor to modulate T2DM onset and AD risk.
3.3. Gut Microbiota
Gut microbiota encodes over three million genes producing thousands of metabo-
lites with diverse roles, including extraction, synthesis, and absorption of many nutrients
and metabolites [81]. Gut microbiota also shows an immune function against pathogenic
bacteria colonization and promotes intestinal epithelium integrity [82–84]. It implies a
wide range of microorganisms, being the dominant phyla Firmicutes and Bacteroidetes,
which represents 90 percent of gut microbiota. Actinobacteria, Proteobacteria, Fusobacteria,
and Verrucomicrobia, are also representative groups [85]. The human gut microbiota suffers
taxonomic and functional modifications in each part of the gastro-intestinal tract. This leads
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to several variations in the same individual, due to age and environmental factors, although
microbiota functions are preserved among individuals [86]. Additionally, modifications
in the diversity or structure of gut microbiota known as dysbiosis, can affect metabolic
activities, resulting in metabolic disorders, like obesity and diabetes. Consequently, dys-
biosis may play a crucial role in the development of T2DM [32,87]. In this sense, it has
been described that type 1 diabetes and T2DM patients show microbiota dysbiosis [88],
which contributes to the onset and maintenance of insulin resistance [37]. Additionally, di-
etary habits can influence gut microbiota composition. In this sense, the Western diet (WD),
a high-fat/high-sugar diet and low fiber intake, induces dysbiosis and it is associated with
obesity and metabolic diseases [89]. On the other hand, studies using the MD have shown
the benefits of modifying the intestinal microbiota in obese subjects for the prevention of
the development of T2DM [89].
On the other hand, the brain-gut-microbiota axis also relates microbiota with brain
pathologies like AD and Parkinson’s disease [90,91]. Thus, AD patients present decreased
microbial diversity, including reduced Firmicutes, and increased Bacteriodetes [92]. Further-
more, dementia patients with amyloidosis have increased pro-inflammatory cytokines lev-
els in blood accompanied by increased pro-inflammatory intestinal bacteria [93]. It should
be noted that several genera of gut microbiota can produce or metabolize neurotransmitters,
such as γ-aminobutyric acid (GABA) [94], which play a relevant role in brain aging [95].
These findings position gut bacterial communities as a target for therapeutic intervention.
Moreover, given the close relation between AD and metabolic alterations, gut microbiota
could provide a relevant link between both pathologies. In this sense, undigested foods, mi-
crobes, endotoxins and immune response cause chronic inflammation that may ultimately
contribute to alter the BBB integrity and trigger neuroinflammation [96]. Interestingly,
a recent study shows that obesity, highly present in T2DM patients, impairs short-term and
working memory through gut microbial metabolism of aromatic amino acids [3], offering a
new venue that relates metabolic alterations and cognitive impairment.
4. Diet, Inflammation and Gut Microbiota in AD Models
Mouse models offer a good approximation to study human gut microbiota and their
implications in diseases and inflammatory processes [97,98]. Despite appreciable dif-
ferences between the intestinal tract of mice and humans [97], they share anatomical
and physiological similarities [98]. Interestingly, whereas there are many variations at
lower taxonomic level, gut microbiota composition shows similarities at a higher tax-
onomic level [99]. According to KEGG (Kyoto Encyclopedia of Genes and Genomes)
database [100], when microbiome is analyzed dissimilarities are limited at functional
level and mouse and human share 95.2% of the KEGG orthologous groups. Nevertheless,
mice and humans only share 4.0% of the genes [99]. The mouse microbiome seems to
have specifically enriched pathways involved in membrane transport, biodegradation and
amino acids metabolism [99,101].
Diet and housing conditions may markedly influence the composition of the gut
microbiome [84,99,102] together with the age [103], gender [104] and the genotype of
the mice [105,106]. However, gut microbiome in mice is mainly composed by bacteria
belonging to the phylum Bacteroidetes, followed by phyla Firmicutes, Deferribacteres [99,101]
and Proteobacteria [107], although the actual order depends on the studies [99].
As previously stated (Section 3.3. Gut microbiota), AD patients [108,109] and AD
preclinical models [110,111] present significant dysbiosis and alterations in the composition
of the microbiome. Concretely, APP/PS1 mice dysbiosis leads to alterations in metabolic
and cellular pathways, including the phosphatidylinositol signaling system, limonene
and pinene degradation, as well as butanoate/pyruvate metabolism [111]. Microbiome
and their secretory products, such as lipopolysaccharide (LPS), are toxins that play a
key role in the immune response [112,113] and are involved in microglial activation [114].
SCFAs (acetate, propionate and butyrate) are products of anaerobic bacteria fermentation of
dietary fibers in the intestine. SCFAs are relevant gut-microbiota mediators of inflammation
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and immune response [115,116], they have a protective effect on epithelial cells [117] and
decrease Aβ fibrillation in vitro [118]. Propionate, a potent neurotoxic agent, is increased
in 3xTg-AD mice by 6 months of age [119]. On the other hand, the concentration of
SCFAs, including butyric and isobutyric acids, tend to be lower in both feces and brains
from 3xTg-AD mice [111,119]. Likewise, gut microbiome can modulate the inflammatory
response in both, the intestinal tract and the brain, through gut-brain axis [115,120,121].
Besides, gut microbiota is critical for microglia maturation [122,123] and activation in the
CNS [122,124]. Activated microglia cells are significantly increased in the brains from
11-month 3xTg-AD mice [119] and, in germ-free APP/PS1 mice, a reduction of cortical
microglia cells has been reported at 3.5 and 8 months of age [124]. Additionally, pro-
inflammatory cytokines IL-6 or IL-1β, as well as lipocalin-2 or TNF-α expression levels are
increased in the colon of APP/PS1 mice by 3 and 6 months of age [125]. Similar results have
been observed in SAMP8 mice, a spontaneous AD model, with colonic inflammation and
high IL-1β levels [126]. Moreover, IL-1β was increased, while IFN-γ, IL-2 and IL-5 levels
decreased in the brain from aged APP/PS1 mice [124]. In addition, a similar cytokines
profile can be observed in plasma from 14-month 3xTg-AD mice, with higher levels of
pro-inflammatory cytokines such as IL-12p40, whereas IL-1α, IL-1β, IL-3, IL-5, IL-6, IL-12
p70, IL-17, TNF-α, IFN-γ, CCL2, CCL3, CCL5, CCL11 and GM-CSF are decreased [127].
Gut-brain axis and gut microbiome seem to be fundamental for the load of Aβ in
the brain [124,128]. Previous studies have shown that germ-free APP/PS1 (amyloid pre-
cursor protein/presenilin 1) mice, have lower levels of Aβ, mainly Aβ42, in brain and
plasma, whereas colonization by microbiota from aged APP/PS1 mice results in increased
levels of Aβ, supporting a close cross-talk between gut and brain in AD [124]. Moreover,
APP/PS1 mice on long-term antibiotics treatment (gentamicin, vancomycin, metronida-
zole, neomycin, ampicillin, kanamycin, colistin and cefaperazone) show lower Aβ plaque
deposition and higher soluble Aβ production, favoring Aβ42 formation in the cortex and
hippocampus [129]. In addition, wildtype fecal solution administered to APP/PS1 mice,
previously treated with antibiotics, also results in lower Aβ deposition and better cognitive
performance [130]. Similar outcomes have been described in ADLPAPT mice after transfer-
ring fecal microbiota from wildtype mice for 4 months. Treated ADLPAPT mice show lower
SP burden and lower Aβ levels [128].
Differences in gut microbiota are observed when wildtype and AD mice are com-
pared (Table 1) [107,111,131]. Previous studies have reported lower bacterial diversity and
more similar bacteria composition when young AD mice are compared with wildtype
counterparts [90,107,132], while further differences are shown as the age of the animals
increase [90]. Following this idea, gut microbiota from young APP/PS1 mice [107] and
5xFAD mice [131,133] are similar to that observed in wildtype animals. No significant differ-
ences in either α- or β-diversity have been observed in 5xFAD mice at 9–10 weeks old [133],
although α-diversity is lower in these mice by 6 and 12 months of age [134]. Nevertheless,
α-diversity, that conveys the diversity of species within a single sample, is significantly
higher in wildtype mice compared to APP/PS1 mice by 9 months of age [135], although
other studies have reported higher α-diversity in the microbiota of APP/PS1 mice at the
same age [90]. It also seems that α-diversity is diminished with aging in APP/PS1 mice,
as an indication of a worse health status of the host with aging [132]. On the other hand,
β-diversity shows significant differences in the microbiome composition of APP/PS1 mice
by 2, 6 [90] and 9 months of age [135] when compared with their wildtype counterparts. So,
as disease progresses a marked temporal shift in the taxonomic distribution of principal
phyla is detected, and the Firmicutes/Bacteroidetes ratio increases in APP/PS1 [107] and
5xFAD mice [131,134] in an age-dependent manner. An increase in Firmicutes/Bacteroidetes
ratio is also observed when bacterial extracellular vesicles are analyzed in the serum of
8-month APP/PS1 mice [136]. Nevertheless, the ratio Firmicutes/Bacteroidetes is decreased
in APPNL-G-F mice at this age [137], underlying the complexity of these studies.
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Table 1. Alterations of gut composition in AD preclinical models.
Phylum Class Family AD Mice Ref.
Actinobacteria Actinobacteria
Turicibacteriaceae = in APP/PS1 miceat 6–24 months of age [107]
Coriobacteriaceae ↑ in APP/PS1 miceat 6–8 months of age [132]
Bacteroidetes Bacteroidia
Rikenellaceae ↓ in APP/PS1 miceat 6–24 months of age [90,107]
Bacteroidaceae (Genus
Prevotella)
↓ in APP/PS1 mice
at 3–6–8 months of age [90,132]
↓ in 5xFAD mice
at 6–12 months of age [134]
↑ in 3xTg-AD at 11 months of age [119]
Firmicutes
Erysipelotrichia Erysipelotrichaceae ↑ in APP/PS1 miceat 24 months of age [107,111]
Clostridia
Ruminococcaceae
↓ Genus Ruminiclostridium in tg2576 mice
at 6–15 months of age [138]
↓ Genus Ruminococcus in APP/PS1 mice
at 6–8 months of age [111,132]
↑ Genus Ruminococcus in 5xFAD mice
at 6–12 months of age [134]
Clostridiaceae
↓ Butyricicoccus pullicaecorum in APP/PS1
mice at 8–12 months of age [111]
↑ transiently Clostridium leptum in
5xFAD mice
at 9 weeks of age
[139]
Lachnospiraceae
↑ in APP/PS1 mice
at 3 months of age [90]
↑ in 5xFAD mice




↑ in Tg2576 at 6 months of age/= at
15 months of age [138]
↓ in APP/PS1 mice
at 8 months of age [140]
↑ in 3xTg-AD mice
at 11 months of age [119]
↓ in 5xFAD mice




↑ in APP/PS1 mice
at 6 months of age [107]
↑ in 5xFAD mice at 6–12 months of age [134]
δ-proteobacteria Desulfovibrionaceae
(Genus Desulfovibrio)
↑ in APP/PS1 mice
at 5–9 months of age [111,130,132]
↑ in 5xFAD mice
at 6–12 months of age [134]
ε-proteobacteria Helicobacteraceae
↑ in APP/PS1 mice
at 3–6–8 months of age [132]
↑ in 5xFAD mice at 6 months of age/↓ at
12 months of age [134]
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Table 1. Cont.
Phylum Class Family AD Mice Ref.





at 2–12 months of age [90,111,130]
N.D. in 5xFAD mice at 9 weeks of age/↑ at
12 months of age [134,139]
N.D.: not detected; =: no differences; ↓: decrease; ↑: increase; ↑↑: strong increase.
Gram-negative phylum Bacteroidetes, that are the main producers of acetate and propi-
onate [141], seem to steadily increase with aging in both APP/PS1 and wildtype animals,
but they are less abundant in APP/PS1 mice, being families Rikenellaceae [90,107] and
Bacteroidaceae (genus Prevotella) [132] significantly lower in APP/PS1 mice [90]. A similar
pattern is observed in 5xFAD mice at 6 and 12 months of age [134]. Oppositely, genus Pre-
votella seems to be increased in 3xTg-AD mice by 11 months of age [119].
On the other hand, gram-positive phylum Firmicutes, the main butyrate producing-
bacteria [141], increases with age and has higher presence in APP/PS1 animals than in
wildtype mice by 24 months of age [107]. Similar outcomes have been reported in 5xFAD
mice by 9 weeks of age [139] and in 15-month tg2576 mice [138]. This increase in Firmicutes,
observed in AD models, is mainly due to members of the family Erysipelotrichaceae [107] and
detected dysbiosis develops an immunogenic reaction [142] that is correlated with increased
levels of proinflammatory cytokines, such as TNFα [143]. By contrast, a decrease in the
number of SCFAs and butyrate-producing bacteria is found in AD models. So, families
Ruminococcaceae and Clostridiaceae (class Clostridia) are significantly decreased in 8–12-month
APP/PS1 mice, accompanied by altered butanoate/pyruvate metabolism [111]. There is a
positive correlation between the abundance in family Ruminococcaceae and the concentration
of hypoxantine [144], an intermediate metabolite of purines which has a critical role in
the maintenance of the intestinal barrier function [145] and it is altered in 6-month tg2576
mice [138]. Moreover, genus Ruminococcus (family Ruminococcaceae) is significantly lower
in 8-months APP/PS1 mice, when spatial learning is aggravated in these mice [132].
Conversely, family Ruminococcaceae is increased in 5xFAD mice by 6 and 12 months of
age [134] and it has been reported that Clostridium leptum is transiently increased in feces
of 5xFAD mice at 9 weeks old, as a reflection of a compensatory mechanism in the early
phases of AD [139].
In addition, 5xFAD mice have increased δ-, γ- and ε-Proteobacteria by 6 months of
age, while at 12 months β- and δ-Proteobacteria are increased and ε-Proteobacteria is de-
creased when compared with wildtype counterparts [134]. In line with these observa-
tions, genus Desulfovibrio is reported to be highly increased in 5 to 9 month-old APP/PS1
mice microbiome [90,111,130,132]. As part of this phylum, the genus Sutterella (class β-
Proteobacteria) is significantly increased in APP/PS1 mice in an age-dependent manner [107]
and similar outcomes have been reported in 5xFAD mice at 12 months old [134]. Sutterella
spp. specifically induces mild or negligible inflammatory responses and does not alter
epithelial monolayer integrity [146], although they are increased in feces from patients
with cognitive disorders [147]. Nevertheless, their immunomodulatory role is not fully
understood [148]. Enterobacteriaceae is also increased in the microbiome of APP/PS1 mice
by 6 months of age [90]. On the other hand, phylum Verrucomicrobia, and its only known
genus, mucin-degrading bacteria Akkermansia, down-regulates the expression of the pro-
inflammatory cytokines TNF-α and IFN-γ in the colon [149]. Akkermansia is significantly
increased in APP/PS1 mice along lifespan, starting at 2 months of age [90] up to 7 [130] and
12 months of age, when it is dramatically increased [111]. In 5xFAD mice, the presence of
this phylum is limited in young mice, when compared to their wildtype counterparts [139],
while it increases by 12 months of age [134].
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The overall dysbiosis detected in AD mice (Table 1) leads to a proinflammatory mi-
crobiome that contributes to the inflammatory process [150]. As previously stated, dietary
habits strongly influence the gut microbiota composition [84,102]. Therefore, new strate-
gies try to favor a healthy microbiome through the administration of pre- and probiotics
supplements as a possible treatment for AD [151]. In line with this, 3xTg-AD mice orally
fed with probiotic SLAB51 (Streptococcus, Bifidobacteria, Lactobacilli) presented higher levels
of Bifidobacterium spp. and reduced levels of Campylobacterales, along with an increase
of anti-inflammatory SCFAs and cytokines that down-regulate inflammatory response.
A reduction of amyloid load is also detected, accompanied by an improvement of cognitive
alterations [152]. In other study, FRAMELIM® (Bifidobacterium, Lactobacillus, vitamins A,
D and omega 3 fatty acid) administration to APP/PS1 mice successfully reduced brain
Aβ burden, despite lowering the abundance of butyrate-producing bacteria [153]. An-
tioxidants, such as PW5 have also provoked a shift in gut microbiota composition from
APP/PS1 mice, making them more similar to wildtype counterparts, while reducing SP in
the hippocampus [154]. Although it has been described that pre- and probiotics have little
effect on the microbiome of healthy population [155], the complexity of this research venue
may require more in depth studies to fully elucidate their specific roles on microbiome
and inflammation [156].
Caloric restriction diets have also been associated with an increase of dendritic spines
in the dentate gyrus and cognitive protection in mice [157]. Intermittent fasting (IF) has
also shown beneficial effects on neuropathological characteristics and cognitive deficits
in AD [158–161]. IF leads to ketogenic metabolism, increasing β-hydroxybutyrate lev-
els in serum and CSF [162]. Interestingly, β-hydroxybutyrate protects against Aβ tox-
icity [163,164] and protects hippocampal murine neurons [165,166]. Whereas previous
studies have reported no significant effects of IF on neuroinflammation, synaptic plasticity
or cognitive function in 6-month 5xFAD mice [167], it has also been shown that IF restores
aquaporin-4 polarity, reduces SP deposition and ameliorates cognitive dysfunction in
APP/PS1 mice [168]. Cognitive impairment is also improved in APPNL-G-F mice after IF
for 9 months, whereas no significant effect is observed in amyloid load [169]. It has also
been reported that IF for 3 months may increase brain-derived neurotrophic factor (BDNF)
and neuronal differentiation in the dentate gyrus from 3xTg-AD mice [170]. In line with
these observations, it has been shown that ketogenic diet reduces amyloid deposition and
tau pathology, improving learning and memory tasks in a 3xTg-AD mouse model [171].
5. Diet, Inflammation and Gut Microbiota in T2DM Models
As previously stated, T2DM includes a heterogeneous group of metabolic disorders,
characterized by hyperglycemia, and influenced by both genetic and environmental fac-
tors [172,173], in which lifestyle and dietary habits are strongly implicated [174]. The most
commonly used T2DM mouse models are based on leptin signaling impairment [175],
including db/db and ob/ob mice. Diet-induced models are also widely used, and different
types of high-fat diet (HFD) are regularly administered to induce prediabetes, as well as to
resemble the effects of WD [176–181]. HFD feeding increases body weight, leptin and in-
sulin levels as well as insulin resistance in rodents [176,182,183]. Interestingly, the effects of
HFD administration seems to be influenced by gut microbiota and the genetic background
of the animals under study [184].
Inflammatory cells including neutrophils, abnormal lymphocytes and monocytes
are increased in db/db mice [185]. In line with these observations, CD68 mRNA, as a
macrophage marker, is highly expressed in white adipose tissue in these mice [186]. In the
CNS of db/db mice, microglia cells are also increased [63] and exhibit greater reactivity to
LPS stimulation [187]. In fact, LPS serum levels are markedly increased in db/db mice [188].
Cytokines profile is also affected and db/db mice and previous studies have shown
an increase of pro-inflammatory cytokines, including IL-1β and TNF-α in serum [185],
hippocampus [187] and liver [189]. CCL2, a chemokine that recruits monocytes and
macrophages, is highly expressed in epididymal adipose tissue of db/db mice [186],
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whereas the expression of nucleotide-binding-oligomerization domain type-1 (NOD1) is
suppressed [186]. Inflammation also affects the vasculature and inflammatory markers such
as monocyte chemotactic protein-1 (MCP-1), vascular cell adhesion molecule-1, (VCAM1),
intercellular adhesion molecule-1 (ICAM1) or E-selectin are increased in aortic and carotid
vessels from db/db mice [190]. Likewise, oxidative stress markers, as like 3NT-positive
protein, are increased in serum [191].
The ob/ob mouse also presents chronic inflammation of the adipose tissues which
contributes to the metabolic pathogenesis of obesity and insulin resistance [177,192,193].
Cytokines and chemokines like TNF-α, IL-1β, IL-6, and CCL2 are overexpressed in visceral
adipose tissue [177,194]. In line with these observations, elevated TNF-α levels lead to a
decrease in Azgp1 mRNA and protein levels in adipose tissues of ob/ob mice [177,192].
Additionally, IL-6, TNF-α [195–197], IL-1β, IL-10 [193] and plasminogen activator inhibitor-
1 (PAI-1) are increased in the adipose tissue and the spleen of ob/ob mice [195,197]. IFN-γ
expression decreases in ob/ob mice [193] and other studies have reported lower adiponectin
values in the adipose tissue and in the spleen [193,195]. Moreover, LPS levels are higher
in plasma from ob/ob mice [198] and in C57BL/6NTac mice on HFD [174]. Additionally,
NF-kB levels are elevated in the brain of ob/ob mice [196]. Other markers, such as CD11
and CD86 are increased in the brain and visceral fat tissue, whereas the expression of CD206
decreases [196,197]. In line with these observations, oxidative stress is also severely affected
in ob/ob animals and increased protein oxidation and lipoperoxidation are observed,
accompanied by lower activity of antioxidant enzymes in kidney and heart [195].
As previously pointed out, diet is also an experimental approach to reproduce
metabolic complications and mice fed a WD show infiltration of lymphocytes and neu-
trophils in the liver, indicating the presence of steatohepatitis, and increased TNF-α-positive
macrophages [199]. Animals on WD overexpress pro-inflammatory markers such as IL-1β,
IL-6, TNF-α, FOXP3, SAA1, CCL17, CCL20 and ICAM-1 in the brain [185,199] and CD68
expression is also increased in these mice [186]. The expression of NOD-1 is suppressed in
mice fed with WD [186]. Following these observations, animals on HFD show an increase
of crown-like structures and up-regulation of pro-inflammatory genes, indicating adipose
tissue inflammation associated with diet [200]. Interestingly, whereas adipose tissue in-
flammation is observed after administration of HFD for 24 weeks, hepatic inflammation
is not detected up to 40 weeks on HFD [200]. Moreover, adipose inflammation seems to
contribute to insulin resistance more severely than hepatic inflammation [200]. In addition,
He et al. found out that the phenotypic switch in adipose tissue from anti-inflammatory
to pro-inflammatory macrophages is detected after 5 weeks on HFD, while metabolic
inflammation is noted after 9 weeks [201]. An overall increase of pro-inflammatory cy-
tokines such as TNF-α, IL-6, leptin and TGFβ1 is detected in the liver of HFD-fed mice
for 17 weeks [202] and up to 40 weeks [200]. Moreover, other markers, such as MCP-1,
PAI-1 and CCL2 are increased in adipose tissue of mice on HFD for 9 weeks [176] or up to
17 weeks [202].
The gut microbiota in T2DM mice seems to be highly dependent on the genetic back-
ground and age of the animals under study [203–205] (Table 2). In ob/ob and db/db
mice Bacteroidetes and Firmicutes are the dominant phyla in the gut microbiota [203,206],
followed by Proteobacteria, Tenericutes, Actinobacteria and Cyanobacteria [203,207]. Other less
abundant phyla found in these mice are Acidobacteria, Deferribacteres, Gemmatimonadetes,
Lentishphaerae and Verrucomicrobia [205,208]. Additionally, the ratio Bacteroidetes/Firmicutes
is higher in db/db mice, than on C57Bl/6J mice [205]. On the other hand, family Murib-
aculaceae is reduced in db/db mice by 8 months of age [209], while other studies have
reported that genus Rikenella (family Rikenellaceae) is increased in db/db mice by 6 months
of age [210]. It also seems that genera Paraprevotella and Alloprevotella, (family Prevotellaceae)
are increased in db/db mice by 6 months of age, while the genus Alloprevotella decreases by
8 months of age [209,211]. Families Enterococcaceae and Planococcaceae (class Bacilli) [211],
as well as genus Klebsiella (Enterobacteriaceae) are also increased in db/db mice by 6 months
of age [211].
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Table 2. Alterations of gut composition in prediabetes and T2DM preclinical models.
Phylum Class Family Diabetes mice (db) Reference
Actinobacteria Actinobacteria




↑ in db/db mice at 8–12–18 weeks of age [205]
Pseudonocardiaceae
(Genus Pseudonocardia) ↑ in db/db mice at 8–12–18 weeks of age [205]
Bacteroidetes
Bacteroidia
Muribaculaceae ↓ in db/db mice by 8 months of age [209]
Rickenellaceae
↑ Genus Rikenella in HFD induced diabetic
mice by 14 weeks of age, after 8 weeks
of feeding
[206]
↑ Genus Rikenella in db/db mice by
6 months of age
↓Genus Alistipes in db/db mice by 20 weeks




↓ in db/db mice by 20 weeks of age/ ↑ by
6-8 months of age [204,209–211]
↓ in ob/ob mice by 8 weeks of age [211]
Bacteroidetes
Prevotellaceae
↑ Genus Paraprevotella in db/db mice by
6 months of age
↑ Genus Alloprevotella in db/db mice by
6 months of age /↓ by 8 months of age
[209,211]





↑ in HFD induced diabetic mice by 14
weeks of age, after 8 weeks of feeding [206]
Enterococcaceae
(Genus Enterococcus) ↑ in db/db mice by 6 months of age [211]
Planococcaceae
(Genus Kurthia) ↑ in db/db mice by 6 months of age [211]
Lactobacillaceae
(Genus Lactobacillus) ↑ in db/db mice by 14 weeks of age [206]
Clostridia
Ruminococcaceae
↑ in db/db by 8 weeks [205]
↑ ob/ob mice by 8 weeks of age
↑ Genera Ruminococcus_1 and Oscillibacter in
ob/ob mice by 15–17 weeks of age
[203,206,211]
Lachnospiraceae
↑ Genus Coprococcus in HFD induced
diabetic mice by 14 weeks of age, after 8
weeks of feeding
[206]
↑ Genera Lachnospiraceae_NK4A136 and
Agathobacter in ob/ob mice by 15–17 weeks
of age
[203,206]
↓ in db/db mice by 20 weeks of age [204]
Clostridiaceae
(Genus Bacteroides) ↑ in ob/ob mice by 8 weeks of age [211]
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Table 2. Cont.
Phylum Class Family Diabetes mice (db) Reference
Proteobacteria
α-Proteobacteria Bradyrhizobiaceae ↑ in db/db mice at 8-12-18 weeks of age [205]
γ-Proteobacteria
Enterobacteriaceae
(Genus Klebsiella) ↑in db/db mice by 6 months of age [211]
Moraxellaceae ↑ in ob/ob mice at 8-12-18 weeks of age [205]
δ-Proteobacteria Desulfovibrionaceae
(Genus Desulfovibrio)
↑ in db/db mice by 12 weeks [205]
↑ in HFD induced diabetic mice by 14
weeks of age, after 8 weeks of feeding [206]
ε-Proteobacteria Helicobacteraceae
↓ Genus Helicobacter in STZ-induced
diabetic mice with cognitive disorder [212]
↑ in HFD induced diabetic mice by 14
weeks of age, after 8 weeks of feeding [206]
Deferribacteres Deferribacteres Deferribacteraceae
↑ Genera Deferribacter and Mucispirillum in
HFD induced diabetic mice by 14 weeks of
age, after 8 weeks of feeding
[206]
↓: decrease; ↑: increase.
Interestingly, previous studies have suggested that T2DM pathology can be ame-
liorated by administering pre- and probiotics that may induce modifications in the mi-
crobiome [213–215]. Following this idea, treatment with Lactobacillus acidophilus reduces
pro-inflammatory cytokines, including IL-8, TNFα, and IL-1β in liver and colon of T2DM
mice [87]. Prebiotic inulin modulates gut dysbiosis, increasing phylum Cyanobacteria and
genus Bacteroides, that positively correlate with higher levels of IL-10 at early stages of
T2DM, and negatively correlate with IL-6 and TNF-α in db/db mice [216]. A reduction of
Ruminiclostridium_6, Deferribacteres and Tenericutes is also detected in inulin-treated T2DM
mice, that correlates with IL-6, TNF-α and IL-17A levels [216]. Additionally, diet sup-
plements such as polysaccharides from mulberry fruit [217] and Alpinia oxyphyla Miq.
extract [218], show beneficial effects at microbiome level in db/db mice. Likewise, supple-
mentation with Alpinia oxyphyla Miq. extract increases Akkermasia spp. while Helicobacter
spp. is significantly reduced in db/db mice [218]. Zhang et al., have reported that berberine
and metformin treatment reduces LPS serum levels, relieve intestinal inflammation and
repair intestinal barrier structures [188]. This treatment modifies gut microbiome in db/db
mice, increasing the number of SCFAs producing bacteria and Lactobacillus and Akkermansia,
while decreasing opportunistic pathogens [188]. On the other hand, sodium-butyrate sup-
plementation also ameliorates diabetic inflammation in db/db mice, decreasing LPS and
HbA1c. It also decreases the ratio Firmicutes/Bacteroidetes [185]. In mice on HFD, 15 weeks
treatment with baicalin, a flavonoid used in traditional Chinese medicine, rebalances the mi-
crobiota and SCFAs-producing agents specifically, to protect the intestinal system. Baicalin
seems to regulate metabolic and immunological processes implicated in T2DM [219]. In line
with these observations, another study, using the JinQi Jiangtang (Coptis chinensis, Astra-
galus membranaceus and Lonicera japonica), has reported reduced levels of TNF-α and IL-6,
ameliorating the inflammatory response and regulating the intestinal microbiota [205].
Diabetic mice treated with A. membranaceus also show increased microbial diversity and
enrichment of the bacterial Firmicutes spp., Acidobacteria and Gemmatimonodetes [212].
On the other hand, db/db mice on IF show a reduction of NFκB activation and
decreased LPS levels, associated with a significant improvement of cognitive function,
limited neuroinflammatory response, restructured gut microbiota and metabolites [27,220]
and reduced insulin resistance [207]. Other studies in db/db mice on IF regimen for
28 days have reported a reduction of Enterococcus, Streptococcus, Enterococcaceae, Arthromitus,
Rummeliibacillus that cause inflammation, while increasing Lactobacillus, accompanied by
the attenuation of behavioral alterations [207].
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6. Microbiota, Inflammation and Diet in Preclinical Mixed Models in AD-T2DM
The close relation between AD and T2DM has been largely documented [9,221–224].
While still limited, previous studies have reported the presence of AD-like pathologi-
cal features related to alterations in the microbiota [207,212,216,225,226] and the inflam-
matory response [227] in animal models that reproduce different metabolic alterations,
suggesting that the gut-brain axis may explain the molecular similarities that link AD
and T2DM [228,229]. Following this idea, it has been described that chronic bacterial
infections are associated with amyloidosis, one of the pathological features shared by AD
and T2DM [227].
Apolipoprotein E (APOE) 4 gene allele, the highest genetic risk factor for developing
late-onset AD, is associated with increased Aβ load, neuroinflammation and alterations in
brain insulin signaling [230–233]. Studies on E4FAD mice, obtained for breeding 5xFAD
mice with homozygous APOE4 mice, have shown that soluble Aβ42 levels and total Aβ
levels are higher when compared to E2FAD and E3FAD mice. Moreover, SP deposition
is higher and more compact in E4FAD mice, leading to neuroinflammation in the hip-
pocampus [234]. ApoE-/- mice on HFD have also shown higher APP expression [235] and
increased Aβ levels [236]. No significant differences have been observed in the expression
of doublecortin or PSD95 in ApoE-/- and APOE4 mice on HFD, indicating that HFD does
not affect neurogenesis and synaptic plasticity [237]. Some studies have shown that WD
administration to adult APP/PS1 mice does not result in increased SP deposition or soluble
Aβ levels compared to animals on ND [238]. Nevertheless, the vast majority of avail-
able bibliography supports the deleterious effect of HDF administration. HFD increases
hippocampal Aβ deposition in 5xFAD mice with no significant effect on memory [239].
APP/PS1 mice on HFD present a lower percentage of spines and deterioration of newborn
neurons when compared with wildtype mice on normal diet (ND) [240]. Similarly, an exac-
erbation of synaptic loss has been detected in APP/PS1xdb/db mice [241]. Other studies
have reported increased amyloid and tau pathologies, vascular damage and cognitive
impairment in APP/PS1 mice on HFD [64]. Even short-term HFD [242] increases tau
phosphorylation [236] and cognitive impairment is also increased 3xTg-AD on HFD [243].
Cognitive deficits might be due to loss of synaptic plasticity, since a reduction of matrix
metalloproteinases 2/9 activity accompanied by a decrease in the expression of the BDNF
gene have been reported [238].
An overlap in the inflammatory mechanisms has also been described in AD and
T2DM [244]. Previous findings confirmed that the microglial receptor for advanced gly-
cation end products in T2DM may mediate microglial activation and neuroinflammation
AD brains [244,245]. Increased neuroinflammation might not be exclusively related to
HFD, since wildtype mice on HFD do not show a significant increase in the number of
activated glial cells in the hippocampus, supporting a synergistic contribution when AD
and metabolic disease are set together [240], as regularly observed in the clinic. MIP-1α,
IL-1β, and IL-17 are altered in the cortex from APP/PS1 mice on HFD that also show
increased IL-1β and TNF-α, accompanied by gliosis and disrupted neurogenesis in the
hippocampus [12,240]. Higher levels of circulating blood monocytes, MCP-1, and ox-LDL
are also observed in plasma from these mice, indicating severe systemic inflammation
in these animals [238]. Interestingly, IL1-β, IL-12p70 and IL-13 correlate with insulin
levels in APP/PS1xdb/db mice and IL-3, IL-17, IL-4, and KC (CXCL1) are also affected
in these mice [12], suggesting that specific cytokine profiles are associated with AD and
T2DM. In line with these observations, microglial activation is also increased 3xTg-AD
on HFD [246].
An exacerbated production of pro-inflammatory cytokines, such as IL-1, IL-6 or TNF-α
is observed in APOE4 mice [247]. Moreover, FAD mutations induce neuroinflammation
in the hippocampus of APOE4 mice, by inducing the expression of genes for chemokine
ligand 4, low-affinity Fc IgG receptor 4, chemokine 10 of the CXC motif, and α-integrin
increased [248]. On the other hand, ApoE-/- and APOE4 mice show significantly more
inflammation in CA1 when fed with ND than wildtype mice, but these mice treated with
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HFD show decreased CD68 immunoreactivity in the hippocampus [237]. Furthermore,
microbiome related inflammation may play a role at this level [249–251] since wildtype
and ApoE-/- mice on HFD present higher LPS plasma levels and a higher expression of
cytokines in the colon and hippocampus [235]. LPS induced endotoxemia in APOE4 mice
results in an increase of plasma TNFα and G-CSF when compared with APOE3 mice.
Besides, CD8+ T cell apoptosis is observed in APOE4 mice after LPS injection [249].
Diet-induced intestinal dysbiosis produces an imbalance in the microbiota that can
have inflammatory consequences in the AD brain [106]. Interestingly, alteration of brain
function and gut microbiota have been related to HFD administration during gesta-
tion [252]. Therefore, the disbalance in the composition of the gut microbiota could explain
the altered eating behavior, memory impairment and abnormal exploratory performance of
the offspring from mothers on HFD. Moreover, these studies may support the implications
of early-life alterations in later development of neurodegenerative complications [253].
Specific assessment of 3xTg-AD mice on HFD showed a severe lack of the families
Muribaculaceae, Peptococcaceae (genus rc4.4), Dehalobacteriaceae, accompanied by an excess of
genus Clostridium (Table 3) [106]. This study confirms that HFD and genetic predisposition
to neurodegenerative diseases share abnormalities in the microbiome and metabolome
that are unfavorable for brain health. On the other hand, microbiota alterations associated
with APOE have been found at 4 and 6-months of age, including changes in Prevotellaceae,
Rikenellaceae, Gastranaerophilales, Lactobacillaceae, Peptococcaceae, Erysipelotrichaceae (genus
Turicibacter), Desulfovibrionaceae and Mycoplasmataceae (genus Mollicutes) [250]. Moreover,
E4FAD mice had a greater α-diversity but reduced relative abundance of beneficial gut
microbiota (Prevotella and Lactobacillus), accompanied by an increase of pro-inflammatory
microbiota (Escherichia, Turicibacter and Akkermansia) (Table 3) [248]. However, Lactococcus,
that has been implicated in a better performance in behavioral tests, is not present in
ApoE−/− animals [235].
Table 3. Alterations of gut composition in AD and metabolic disease animal models.
Phylum Class Family Mixed-Model (AD-Metabolic Disease) Ref.
Bacteroidetes
Bacteroidia Muribaculaceae ↓ in 3xTg-AD-HFD mice [106]
Bacteroidetes Prevotellaceae ↓Genus Prevotella in E4FAD mice [248]
Firmicutes
Erysipelotrichia Erysipelotrichaceae ↑ Genus Turicibacter in E4FAD mice [248]
Clostridia
Clostridiaceae ↑↑ Genus Clostridium in 3xTg-AD-HFDmice [106]
Dehalobacteriaceae ↓ in 3xTg-AD-HFD mice [106]
Peptococcaceae ↓ in 3xTg-AD-HFD mice [106]
Bacilli
Lactobacillaceae ↓ Genus Lactobacillus in E4FAD mice [248]
Streptococcaceae Genus Lactococcus not present inAPOE-/- mice [235]
Proteobacteria γ-proteobacteria Enterobacteriaceae ↑ Genus Escherichia in E4FAD mice [248]
Verrucomicrobia Verrucomicrobiae Verrucomicrobiaceae(Akkermansia spp.) ↑ in E4FAD mice [248]
↓: decrease; ↑: increase; ↑↑: strong increase.
Caloric restriction has been considered an experimental diet that can lengthen the lifes-
pan in various animal models [254–256] and may help to establish a balanced architecture
of the intestinal microbiota with beneficial effects on the health of the host by reducing the
intestinal antigen load [256]. Other diet strategies to ameliorate AD symptoms are based
in prebiotics such as inulin that stimulates the growth and activity of SCFAs-producing
bacteria. Inulin administration also reduces proinflammatory gene expression in the hip-
pocampus and Aβ deposits in E4FAD mice [248]. It also contributed to a larger size of
the caecum, improving the microbial content, even before the development of the Aβ
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pathology in E4FAD mice. An improvement in systemic metabolism associated to the
modulation of the intestinal microbiome has also observed in this model [248]. Although
further studies would be necessary to understand the functional and morphological char-
acteristics mediated by inflammation, microbiota, and diet in mixed preclinical models
of AD-T2DM, observations based on experimental animal models may contribute to the
development of optimal techniques and therapies to reverse the complications associated
with AD and metabolic alterations.
7. Common Microbiota Alterations in AD, T2DM and Mixed Preclinical Models
AD and T2DM share common pathological features that include impairment in in-
sulin signaling, alteration of amyloid and tau pathologies or vascular damage that have
been largely revised before (Mejido, Penny et al., 2020; Goncalves et al., 2019; Ferreira
et al., 2019; Vieira et al., 2018). At inflammatory level, as stated in this review and in
previous studies, proinflammatory cytokines are favored in AD, T2DM and mixed preclin-
ical models. Among others, it has been shown that IL-1β is increased in the brain from
aged APP/PS1 [124] as well as in APP/PS1xdb/db mice [12]. IL-1β and TNF-α are also
increased in the brain from db/db mice [187] as well as in APP/PS1 mice on HFD [12,240].
Whereas the role of the gut microbiota as a feasible connection between both diseases
remain largely unexplored, some common links have been reported (Graphic Abstract). Bac-
teroidetes and Firmicutes are the dominant phyla in AD, T2DM and mixed models [85,203,206].
Bacteroidetes (family Muribaculaceae) is reduced in db/db mice at 8 months of age [209] and
3xTg-AD mice on HFD also show a severe lack of Bacteroidetes [106]. This phylum (family Pre-
votellaceae) is also decreased in E4FAD and db/db mice at 8 months of age [209,211,248]. Acti-
nobacteria (family Coriobacteriaceae) has been reported to be increased both in APP/PS1 [132]
and in db/db mice [205], while the Bacteroidaceae family seems to be less abundant in different
AD and T2DM preclinical models [90,132,134,204,209–211,257]. Nevertheless, other studies
have reported increases in the Bacteroidaceae family, both in AD [119] and T2DM ani-
mals [204,209–211]. Phylum Firmicutes (family Ruminococcaceae, genus Ruminococcus) has
been reported to be increased in AD [134] as well as in different T2DM preclinical mod-
els [203,205,206]. The Clostridiaceae family is transiently increased in the feces of 5xFAD
mice at 9 weeks [139]. Similarly, it is increased in ob/ob mice at 8 weeks of age [257] and an
excess of the genus Clostridium is observed in 3xTg-AD mice on HFD [106]. Other studies
have reported that the Lachnospiraceae family is more abundant in AD preclinical models
(3 month-old APP/ PS1 mice and 5xFAD mice at 6 months of age) [90,134] as well as in
metabolic disease preclinical models (both after HFD administration and in 15-17 week
old ob/ob mice) [203,206]. Likewise, the family Lactobacillaceae has been shown to be
increased in AD mice (6 month-old Tg2576 and 11 month-old 3xTg-AD mice) [119,138] and
similar outcomes have been reported in db/db mice at 14 weeks of age [206]. Other alter-
ations include increases of the Enterobacteriaceae family in db/db and AD mice, including
6 month-old APP/PS1 [90] and E4FAD mice [248]. The Desulfovibrionaceae family (Genus
Desulfovibrio) is also increased in 5–9 month-old APP/PS1 [111,130,132] and 6-12 month-old
5xFAD mice [134]. Similar outcomes have been reported in 12-week-old db/db mice [205]
and after HFD administration [206]. It has also been shown that family Helicobacteraceae
is increased in 3–8 month-old APP/PS1 mice, 6 month-old 5xFAD mice and after HFD
administration [132,134,206], supporting similar changes in AD and metabolic disease
models. Interestingly, previous studies suggest that AD and T2DM pathologies can im-
prove through the treatment of pre-and probiotics [87,151–153,248,258], caloric restriction
diets [27,157,207,220] or antioxidants [154], helping to regulate intestinal dysbiosis and
reduce the inflammation.
8. Conclusions
The extensive review of available bibliography shows that gut microbiota composition,
and the brain-gut axis are affected in AD, T2DM and mixed models of AD and metabolic
disorders, affecting inflammation through products of bacterial metabolism, like SCAFs.
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Proinflammatory cytokines are widely altered in mouse models of both diseases. Microbiota
is highly affected as diseases progress, and alterations in Actinobacteria, Bacteroidetes or
Firmicutes phyla, among others, are commonly observed in animal models harboring
AD, T2DM or AD and metabolic disease. All these observations based on preclinical
models have contributed to further understand the key role of the gut-brain axis in both
pathologies. Nevertheless, conflicting results have also been reported and therefore further
studies would be necessary to fully understand the relation between diet, microbiota and
inflammation in AD and T2DM.
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